Show simple item record

dc.contributor.authorJones, RJ
dc.contributor.authorHussain, SA
dc.contributor.authorProtheroe, AS
dc.contributor.authorBirtle, A
dc.contributor.authorChakraborti, P
dc.contributor.authorHuddart, RA
dc.contributor.authorJagdev, S
dc.contributor.authorBahl, A
dc.contributor.authorStockdale, A
dc.contributor.authorSundar, S
dc.contributor.authorCrabb, SJ
dc.contributor.authorDixon-Hughes, J
dc.contributor.authorAlexander, L
dc.contributor.authorMorris, A
dc.contributor.authorKelly, C
dc.contributor.authorStobo, J
dc.contributor.authorPaul, J
dc.contributor.authorPowles, T
dc.date.accessioned2017-07-05T10:28:34Z
dc.date.issued2017-06
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 35 (16), pp. 1770 - 1777
dc.identifier.issn0732-183X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/677
dc.identifier.eissn1527-7755
dc.identifier.doi10.1200/jco.2016.70.7828
dc.description.abstractPurpose Two previous single-arm trials have drawn conflicting conclusions regarding the activity of pazopanib in urothelial cancers after failure of platinum-based chemotherapy. Patients and Methods This randomized (1:1) open-label phase II trial compared the efficacy of pazopanib 800 mg orally with paclitaxel (80 mg/m 2 days 1, 8, and 15 every 28 days) in the second-line setting. The primary end point was overall survival (OS). Results Between August 2012 and October 2014, 131 patients, out of 140 planned, were randomly assigned. The study was terminated early on the recommendation of the independent data monitoring committee because of futility. Final analysis after the preplanned number of deaths (n = 110) occurred after a median follow-up of 18 months. One hundred fifteen deaths had occurred at the final data extract presented here. Median OS was 8.0 months for paclitaxel (80% CI, 6.9 to 9.7 months) and 4.7 months for pazopanib (80% CI, 4.2 to 6.4 months). The hazard ratio (HR) adjusted for baseline stratification factors was 1.28 (80% CI, 0.99 to 1.67; one-sided P = .89). Median progression-free survival was 4.1 months for paclitaxel (80% CI, 3.0 to 5.6 months) and 3.1 months for pazopanib (80% CI, 2.7 to 4.6 months; HR, 1.09; 80% CI, 0.85 to 1.40; one-sided P = .67). Discontinuations for toxicity occurred in 7.8% and 23.1% for paclitaxel and pazopanib, respectively. Conclusion Pazopanib did not have greater efficacy than paclitaxel in the second-line treatment of urothelial cancers. There was a trend toward superior OS for paclitaxel.
dc.formatPrint-Electronic
dc.format.extent1770 - 1777
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectUrologic Neoplasms
dc.subjectSulfonamides
dc.subjectPaclitaxel
dc.subjectPyrimidines
dc.subjectAntineoplastic Agents, Phytogenic
dc.subjectAdministration, Oral
dc.subjectDrug Administration Schedule
dc.subjectSurvival Rate
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectKaplan-Meier Estimate
dc.titleRandomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
dc.typeJournal Article
dcterms.dateAccepted2017-04-12
rioxxterms.versionofrecord10.1200/jco.2016.70.7828
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncology
pubs.issue16
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublished
pubs.volume35
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record